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ABSTRACT 
Introduction 
Dopamine transporter imaging with 
123
I-FP-CIT single photon emission computed 
tomography (SPECT) is helpful for the differential diagnosis between Parkinsonian syndrome 
(PS) and essential tremor (ET). Although visual assessment and time-consuming manual 
evaluation techniques are readily available, a fully objective and automated dopamine 
transporter quantification technique is always preferable, at least in research and follow-up 
investigations. Our aim was to develop a novel automated magnetic resonance imaging 
(MRI)-based evaluation technique of dopamine transporter SPECT images and to compare its 
diagnostic accuracy with those of the gold-standard visual grading and manual dopamine 
transporter binding quantification methods. 
Methods 
123
I-FP-CIT SPECT and MRI sessions were conducted in 33 patients with PS (15 men; 
mean age: 60.3±9.7 years) and 15 patients with ET (8 men; mean age: 54.7±16.3 years). 
Striatal dopamine transporter binding was visually classified by 2 independent experts as 
normal or abnormal grade I, II and III. Caudal and putaminal specific uptake ratios were 
calculated by both automated MRI-based and manual evaluation techniques. 
Results 
We found almost perfect agreement (κ=0.829) between the visual scores by the 2 
observers. The automated method showed strong correlation with the visual and manual 
evaluation techniques and its diagnostic accuracy (sensitivity=97.0%; specificity=93.3%) was 
also comparable to these methods. The automatically determined uptake parameters showed 
negative correlation with the clinical severity of parkinsonism. Based on ordinal regression 
modelling, the automated MRI-based method could reliably determine the visual grading 
scores. 
Conclusion 
The novel MRI-based evaluation of 
123
I-FP-CIT SPECT images is useful for the 
differentiation of PS from ET. 
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1. INTRODUCTION 
Dopamine transporter (DAT) single photon emission computed tomography (SPECT) 
imaging with 
123
I-FP-CIT radio-ligand is a useful diagnostic tool for the differentiation of PS 
from ET [1]. 
In clinical practice the 
123
I-FP-CIT SPECT images are most commonly interpreted 
based on careful visual assessment of the striatal tracer binding, which is a simple and 
straightforward approach with high diagnostic accuracy and excellent interobserver agreement 
[2, 3]. However, visual classification is subjective and may be strongly dependent on the 
observer’s experience [4]. In addition to visual interpretation, binding quantification based on 
manual delineation of striatal regions of interest (ROIs) is also readily available. However, 
this laborious technique is still subjective and dependent on the operator [5, 6]. To overcome 
such limitations, several automatic or semiautomatic ROI definition techniques were proposed 
for DAT binding quantification [6-9]. Most of these methods are based on some sort of 
registration between the DAT SPECT and a standard template image. Unfortunately DAT 
images contain relatively few anatomic details (i.e. they display a definite amount of uptake 
only in the striatum), which is further exacerbated by reduced DAT density in patients with 
advanced PS. Thus, registration to the template image may be inaccurate resulting in reduced 
accuracy of ROI delineation and subsequent DAT binding quantification [7]. Besides the 
registration process, generic template based ROIs may yield inaccuracies due to the 
morphological differences between the generic ROIs and the subject specific ROIs [10]. 
ROI delineation based on individual morphology as obtained by image fusion with 
magnetic resonance imaging (MRI) is also an option recommended by the recent European 
Association of Nuclear Medicine guidelines, especially when low DAT binding is expected 
[1]. In a simulation study, Gallego et al. demonstrated that ROIs based on individual 
morphology as obtained from MRI scan yields more accurate results than using template-
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based generic ROIs [10]. Although, reliable automated MRI-based brain segmentation 
methods are available for the striatal structures [11, 12], this type of ROI delineation is not 
commonly used for DAT SPECT evaluation and even in rare cases where it is applied, the 
validation is still lacking [13]. 
The aim of this study was to develop and validate a novel automated MRI-based 
evaluation of DAT SPECT images as a tool for the differentiation between PS and ET and to 
compare the results with a well-established visual grading and DAT binding quantification 
driven by manual delineation of striatal ROIs. We also investigated for potential associations 
between DAT binding parameters and clinical measures of PS severity. 
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2. MATERIALS AND METHODS 
2.1. Subjects 
Thirty-three patients with Parkinsonian syndrome (PS, 15 men and 18 women; mean 
age: 60.3±9.7, range: 39-73 years) and 15 essential tremor (ET) patients (8 men and 7 women; 
mean age: 54.7±16.3, range: 22-78 years) were included in a prospective study. ET patients 
served as the control group. Only patients who did not take any medication which could 
significantly influence striatal DAT binding were included in the study [1]. 
The diagnosis of PS and ET was confirmed by a movement disorder specialist in 
accordance with current clinical criteria [14, 15]. 
The severity of PS was assessed by Hoehn-Yahr scale [16], the Hungarian validated 
version of Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease 
Rating Scale (MDS-UPDRS) [17, 18] and the documented disease duration. Demographic and 
clinical data are presented in TABLE 1. 
All subjects received detailed information on the investigation and gave written 
informed consent prior to the examination. The study was approved by the National Ethical 
Board (36104/2012/EKU). 
2.2. SPECT imaging 
For thyroid blocking, patients received Lugol’s solution (30 drops, 3 times a day, for 3 
days) before tracer administration. Three hours after the intravenous administration of 185 
MBq of 
123
I Ioflupane (DaTSCAN, GE Healthcare), brain SPECT examination with low dose 
computed tomography (CT) was performed. Double head gamma camera (AnyScan, Mediso) 
with low energy high resolution (LEHR) collimator was used. The imaging parameters were 
as follows: 128x128 matrix size; 64 frames; 40 sec/frame; angular step 5.6°; zoom 1.45. 
Transversal, sagittal and coronal slices were created. Images were reconstructed using a 
Butterworth brain prefilter. 
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2.3. Magnetic resonance imaging 
Magnetic resonance imaging was performed on a 3T MRI scanner (MAGNETOM 
Trio a Tim System, Siemens AG, Erlangen, Germany) with a 12-channel head coil. A T1-
weighted 3D MPRAGE (TR/TI/TE=2530/1100/3.37ms; Flip Angle=7°; 176 sagittal slices; 
slice thickness=1mm; FOV=256x256mm
2
; matrix size=256x256; receiver 
bandwidth=200Hz/pixel) sequence was obtained to allow automated MR-based evaluation of 
dopamine transporter (DAT) binding. 
2.4. Visual evaluation  
SPECT images were visually assessed by 2 independent experts blinded to clinical 
data and uptake measures provided by the automated (or manual) analysis. Striatal DAT 
binding was classified as normal or abnormal grade I, II and III in accordance with the criteria 
of Benamer et al. [2]: 
Normal: Tracer uptake bilaterally in putamen and caudate nuclei and largely symmetric. 
Abnormal grade I: Asymmetric uptake with normal or almost normal putamen activity in one 
hemisphere and with a more marked reduction in the contralateral putamen. 
Abnormal grade II: Significant bilateral reduction in putamen uptake with activity confined to 
the caudate nuclei. 
Abnormal grade III: Virtually absent uptake bilaterally affecting both putamen and caudate 
nuclei. 
2.5. Automated evaluation  
Left and right caudate and putamen were automatically segmented on T1-weighted 
MPRAGE images using FIRST [12], while occipital cortex was defined by merging the lateral 
occipital, lingual, cuneus and pericalcarine regions delineated by FreeSurfer 5.3 image 
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analysis suite [19]. 
For automated DAT binding quantification, the segmented masks were aligned with 
each subject’s native DAT image, while keeping the original mask resolution of 1x1x1mm3. 
The alignment was based on the rigid body (6 degrees-of-freedom) transformation between 
MR and CT images calculated by FLIRT [20]. Normalized mutual information was used as 
cost-function. The coregistration process is illustrated in Supplementary Figure 1. 
Mean 
123
I-FP-CIT uptake values were extracted for each mask by InterView
TM
 
FUSION version 2.02.055 (Mediso). Specific to nonspecific uptake ratios were calculated 
separately for the left and right sides of caudate and putamen using the formula: 
(UPTstriatal – UPTocc)/UPTocc 
, where UPTstriatal represents the mean uptake in the target region (putamen or caudate) and 
UPTocc is the mean uptake in the reference region (occipital cortex). 
Since, the underlying disease in patients with PS is often asymmetric, the uptake data 
were defined in terms of the “higher” (less affected) and “lower” specific uptake (more 
affected) sides, rather than left and right hemispheres. For example, “lower” putamen denotes 
the lower one from the left and right putaminal specific uptake ratios. 
2.6. Manual evaluation 
Manual ROI delineation included several steps. 
If 
123
I-FP-CIT accumulation was apparent bilaterally in the putamen and caudate then 
manual delineation was performed as follows: left and right caudate and putamen were 
manually labelled in three axial SPECT slices; the slice showing most intense striatal tracer 
uptake and the most caudal and cranial slices in which the tracer uptake was still evident for 
the given brain structure. Using InterView
TM
 FUSION version 2.02.055 (Mediso), the user-
defined two-dimensional (2D) ROIs were automatically extended between these three slices 
to form a three-dimensional (3D) ROI for each structure. Finally, using the CT images, each 
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3D ROI was manually corrected according to the anatomical landmarks. 
If 
123
I-FP-CIT accumulation was present only in one hemispheric putamen or caudate, 
then the 3D ROI around the best preserved putamen or caudate was outlined based on the 
above. The mirror image of this tracing was used as an initial label for the contralateral side, 
which was adjusted manually based on the CT image to fit individual anatomy. 
If 
123
I-FP-CIT accumulation was visually absent bilaterally in the caudate or the 
putamen, the delineation of the 3D ROI covering the corresponding anatomical structure was 
based on the CT image exclusively. 
Three dimensional ROIs of the occipital reference region were drawn in a way to 
avoid the inclusion of any bone tissue or cerebrospinal fluid.  
Similarly to the automated evaluation, specific to nonspecific uptake ratios were 
calculated separately for the “higher” (less affected) and “lower” specific uptake (more 
affected) sides of the putamen and caudate. For these calculations, the average of the mean 
uptake values from left and right occipital ROIs was used as the nonspecific uptake reference 
(i.e. UPTocc). 
2.7. Statistical analysis 
Statistical analyses were performed using SPSS 20.0 software (IBM Corp., Armonk, 
NY). 
Agreement between the visual uptake scores (normal=0; grade I=1; grade II=2, grade 
III=3) by the 2 observers was evaluated by Cohen’s kappa coefficient (κ). Kappa values were 
interpreted as follows: 0.00-0.20 indicates slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-
0.80 substantial and 0.81-1.00 almost perfect agreement. 
The abilities of visual, automated and manual evaluation methods to differentiate 
between ET and PS patients were assessed by receiver operating characteristic (ROC) 
analysis with clinical diagnosis (PS vs. ET) as reference standard. To describe the 
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discriminative properties, area under the ROC curve (AUC), specificity, sensitivity, positive 
and negative predictive values (PPV and NPV, respectively) were calculated. 
Spearman correlations were performed to assess the relationships among visually, 
manually and automatically determined uptake parameters. The strength of Spearman 
correlations was interpreted based on the value of the correlation coefficient (ρ): 
|ρ|≥0.7=strong; 0.3≤|ρ|<0.7=moderate; |ρ|<0.3=weak. 
Subsequently, regression analysis was performed to evaluate how efficiently the 
automated method can predict the grade of abnormality rated by visual observers. In this part 
of the study, only the scans of those patients were included where visual scores agreed 
between the 2 observers (n=42). Ordinal regression was used to model the dependence of 
visual scores on specific uptake ratios derived from automated method. This analysis was 
performed only for the “lower” putamen; the region providing the best diagnostic accuracy 
(see the results of ROC analysis). After obtaining a significant regression model, Kappa 
analysis was performed to assess the agreement between predicted and actual visual 
categories. 
In the PS group, Spearman correlations were used to assess the correlations of 
visually/manually/automatically determined uptake parameters with clinical measures. In 
these analyses, the visual scores were used as the average between the two observers. 
Results were considered significant at P≤0.05 for all statistical tests. 
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3. RESULTS 
Almost perfect agreement was found between the visual scores by the 2 observers 
(complete agreement in 42/48 cases; only one grade difference was found in 6 cases; 
κ=0.829). Most of the disagreement happened at higher grades (grades 3 vs. 2 in two 
occasions, grades 2 vs. 1 in three occasions, grade 1 vs. 0 in one occasion). All of the patients 
with a clinical diagnosis of PS were visually classified as abnormal (grade ≥ I) by both 
observers. 
To demonstrate the diagnostic accuracy (PS vs. ET) of each method, AUC, sensitivity, 
specificity, PPV and NPV are presented in TABLE 2. The best AUC (=0.988) was achieved 
for the “lower” putaminal uptake ratio derived from the automated method, which was 
comparable to AUCs for the human observers (0.961-0.980) and the putaminal uptake ratios 
derived from the manual method (0.984-0.986). Frequencies of the estimated outcomes (PS 
vs. ET) by each method are presented in Supplementary Table 1. 
The automatically determined specific uptake ratios showed strong correlation with 
the manually determined ones in all 4 regions (“lower” putamen: ρ=0.931; P<0.001; “higher” 
putamen: ρ=0.897; P<0.001; “lower” caudate: ρ=0.814; P<0.001; “higher” caudate: ρ=0.821; 
P<0.001). Visual ratings showed strong negative correlation with both manually and 
automatically determined specific uptake ratios, which was more remarkable in the putamen 
(TABLE 3). The best correlation with visual scores was obtained for the “lower” putaminal 
uptake ratio derived from automated method. 
We could build a significant ordinal regression model between the automated results 
and the visual grades determined by the observers. Our model showed that the “lower” 
putaminal uptake ratio derived from automated method was inversely associated with visual 
scores (P<0.001; Nagelkerke’s R2=0.839). The obtained Nagelkerke’s R2 value was 
considerably high, suggesting a very good fit of the model. The subsequent Kappa analysis 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
indicated substantial (κ=0.635) agreement between the predicted visual scores by the ordinal 
regression model and the actual visual scores by the observers. Complete agreement was 
found in ~74% of the cases and only one grade difference was observed in the discrepant 
cases. 
Concerning the correlation between uptake parameters and the severity of PS (TABLE 
4), all of the examined uptake measures were moderately correlated (|ρ|>0.5; P<0.001) with 
disease duration. Hoehn-Yahr score was also significantly correlated with all uptake 
measures, except the “higher” putaminal uptake ratio derived from the manual method. Scores 
on MDS-UPDRS Part I did not correlate with any uptake measures, while the other MDS-
UPDRS scores showed trends or even significant correlations with most of the uptake 
parameters. Correlation coefficients were negative between clinical severity and the uptake 
ratios and positive between clinical severity and the visual scores. 
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4. DISCUSSION 
Visual assessment of DAT binding is an effective tool in the differential diagnosis 
between PS and ET [2]. However, an objective DAT quantification technique is warranted for 
both clinical and research applicability (e.g. monitoring subtle changes during the progression 
of PS). DAT quantification based on conventional manual ROI delineation is still subjective, 
therefore more complicated methods were proposed to provide objective information on tracer 
binding [6-9]. While the objectivity is improved by these methods, the accuracy may be 
biased by the fact that striatal ROIs are delineated by using DAT SPECT images rather than 
incorporating relevant morphological information (CT or MRI images). 
In this study, we tested a novel automated morphological MRI-based evaluation of 
DAT binding – as applied to the differentiation of PS from ET – and compared it with the 
gold-standard visual grading and conventional manual ROI delineation techniques. 
Our results showed almost perfect interobserver agreement between the two observers 
in visually interpreting 
123
I-FP-CIT SPECT images, which is consistent with an earlier study 
using the same 4-point visual rating scale [21]. Other studies are also reported a high 
interobserver agreement for visual analysis when using only a dichotomous division of 
normal versus abnormal SPECT images [22, 23]. All of the patients with the clinical diagnosis 
of PS were visually classified as abnormal by both observers, therefore none of our patients 
could be considered as so-called SWEDD (Scans Without Evidence of Dopaminergic Deficit) 
patient; a small specific entity of patients clinically diagnosed with Parkinson's disease but 
having normal DAT imaging [22]. 
The ROC analysis suggests that the automated MRI-based evaluation of the putaminal 
region is appropriate for the differentiation of PS from ET with similarly high discriminatory 
ability as the visual grading technique or the manual evaluation of the putaminal region (for 
AUCs see TABLE 2). Actually, the best general discriminability of PS and ET was observed 
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for the “lower” putaminal uptake ratio derived from the automated method (AUC=0.988). The 
high sensitivity (97.0%) and specificity values (93.3%) observed for the automated evaluation 
of the putaminal region were also comparable to those observed for the validated visual 
grading or the manual evaluation of the putaminal region, but please note that these values are 
highly dependent on the actual cutoff points used. Uptake ratios derived from the caudal 
region showed lower diagnostic performance for both the automated and the manual 
evaluation techniques, which is consistent with earlier studies [6, 24]. The lower diagnostic 
accuracy for caudate could be due to partial volume effect and anatomical variability between 
subjects [10], or due to the pattern of Parkinson disease degeneration (i.e. the putamen is more 
affected than the caudate nucleus) [25].  
Uptake scores obtained from the three different methods were strongly intercorrelated. 
Additionally, when the “lower” putaminal uptake ratio derived from the automated method 
was regraded into predicted visual scores, substantial agreement was observed with the actual 
visual scores by the observers. Because in our automated method the “lower” putaminal 
uptake ratio can be reliably transformed into the visual grading scores by an ordinal 
regression model, our automated evaluation technique seems to be valid, reliable and 
congruent with the gold-standard visual evaluation. 
In patients with PS, the automated method showed decreased striatal DAT binding 
with increased disease duration in accordance with the other two evaluation techniques and 
earlier studies [26, 27]. The “lower” putaminal uptake ratio derived from the automated 
method was inversely correlated with clinical measures such as Hoehn-Yahr score, MDS-
UPDRS Total and MDS-UPDRS Parts II, III and IV scores, suggesting that the automated 
evaluation may be effective not only in the diagnosis of PS, but also in the assessment of 
disease severity. Most of the other uptake parameters examined in this study also showed 
trends or even significant correlations with clinical severity, consistently with previous studies 
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[7, 27]. Scores on MDS-UPDRS Part I did not correlate with any uptake measures, which is 
not surprising because MDS-UPDRS Part I describes the disability mainly caused by non-
motor symptoms [17, 28].  
Our study has some inherent limitations. The clinical diagnosis used as a reference 
standard in the ROC analyses may be imperfect [29, 30]. Although in the absence of 
postmortem confirmation of the diagnosis this uncertainty cannot be totally eliminated, but to 
minimize the possibility of any misdiagnosis, all of our patients were examined by the same 
neurologist specialized in movement disorders. Moreover, we tried to reduce chance of 
diagnostic inaccuracy of ET by having patients with disease duration ≥5 years. Another 
potential limitation is that the AUC, sensitivity, specificity, positive and negative predictive 
values may be affected by both the size and the composition of our sample. However, since all 
the three evaluation techniques were tested on the same sample, our results still provide a fair 
representation of their relative performance. 
In conclusion, observer-independent automated DAT quantification methods are 
preferable, at least in research. We developed and validated a novel MRI-based evaluation 
technique of 
123
I-FP-CIT SPECT images that was useful for the differentiation of PS from ET. 
Main advantages of this technique are that it is fully objective and that the ROIs used for the 
evaluation are delineated based on individual morphology rather than using generic template-
based ROIs or the DAT binding itself. Our new approach showed strong correlation with the 
gold-standard visual and conventional manual evaluation techniques and its diagnostic 
accuracy was also similarly good. Additionally, the uptake parameters derived from this new 
method showed correlation with the clinical severity of parkinsonism. The promising nature 
of our results should be further investigated in larger samples and in follow-up studies. 
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9. FIGURE LEGENDS 
Supplementary Fig. 1. Figure illustrating the coregistration process of the automated 
evaluation in a patient with normal (a) and in a patient with abnormal grade II (b) tracer 
uptake as graded by both observers. The pink, light blue and yellow indicate the automatically 
segmented masks of the putamen, caudate and occipital cortex, respectively. The masks were 
generated in the native space of the acquired T1-weighted MR images (shown on the left), 
and were aligned to the space of DAT SPECT images based on the 6 degrees-of-freedom 
(DOF) rigid body transformation between MR and CT images. The aligned masks and MR 
images overlaid with DAT SPECT images are shown on the right. 
 
Table 1. Demographic and clinical data of patients 
 PS (n=33) ET (n=15) 
Gender (M/F) 15 M; 18 F 8 M; 7 F 
Age (years) 60.3±9.7 [39-73] 54.7±16.3 [22-78] 
H&Y 
stage 1: 1 case 
stage 2: 16 cases 
stage 3: 12 cases 
stage 4: 3 cases 
stage 5: 1 case 
n.a. 
Disease duration (years) 6.5±6.1 [1-24] 9.5±3.1 [5-19] 
MDS-UPDRS I 14.1±7.6 [2-27] n.a. 
MDS-UPDRS II 15.0±9.8 [1-37] n.a. 
MDS-UPDRS III 37.0±13.0 [15-62] n.a. 
MDS-UPDRS IV 5.1±3.0 [0-15] n.a. 
MDS-UPDRS Total 71.2±26.4 [26-120] n.a. 
Data are presented as mean ± standard deviation [range]; PS=parkinsonian syndrome; ET=essential 
tremor; M=male; F=female; H&Y=Hoehn-Yahr score; MDS-UPDRS= Movement Disorder Society-
sponsored revision of the Unified Parkinson's Disease Rating Scale; n.a.=not available 
Table(s)
Table 2. Diagnostic accuracy for the various methods of 
123
I-FP-CIT uptake analysis 
Analysis method Region AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
Automated PUTlower 0.988 97.0 (84.2-99.9) 93.3 (68.1-99.8) 97.0 (84.2-99.9) 93.3 (68.1-99.8) 
 PUThigher 0.978 97.0 (84.2-99.9) 93.3 (68.1-99.8) 97.0 (84.2-99.9) 93.3 (68.1-99.8) 
 CAUDlower 0.871 78.8 (61.1-91.0) 86.7 (59.5-98.3) 92.9 (76.5-99.1) 65.0 (40.8-84.6) 
 CAUDhigher 0.859 78.8 (61.1-91.0) 86.7 (59.5-98.3) 92.9 (76.5-99.1) 65.0 (40.8-84.6) 
Manual PUTlower 0.984 97.0 (84.2-99.9) 93.3 (68.1-99.8) 97.0 (84.2-99.9) 93.3 (68.1-99.8) 
 PUThigher 0.986 93.9 (79.8-99.3) 100 (78.2-100) 100 (88.8-100) 88.2 (63.6-98.5) 
 CAUDlower 0.931 81.8 (64.5-93.0) 100 (78.2-100) 100 (87.2-100) 71.4 (47.8-88.7) 
 CAUDhigher 0.893 75.8 (57.7-88.9) 100 (78.2-100) 100 (86.3-100) 65.2 (42.7-83.6) 
Visual1 – 0.961 100 (89.4-100) 80.0 (51.9-95.7) 91.7 (77.5-98.3) 100 (73.5-100) 
Visual2 – 0.980 100 (89.4-100) 86.7 (59.5-98.3) 94.3 (80.8-99.3) 100 (75.3-100) 
AUC= area under the curve; PPV= positive predictive value; NPV= negative predictive value; PUT=putamen; CAUD=caudate; lower means the more 
affected side with lower specific uptake ratio; higher means the less affected side with higher specific uptake ratio; sensitivity, specificity, PPV and NPV 
values at the optimal cutoff point (closest to the upper left corner of the ROC space) are given for the diagnosis of Parkinsonian syndrome; values in 
parentheses represent 95% confidence intervals; Visual1=visual grades by Observer1; Visual2=visual grades by Observer2 
Table(s)
Table 3. Correlations of visual scores with specific uptake ratios 
Analysis method Region 
Visual1 Visual2 
ρ P ρ P 
Automated PUTlower -0.889 <0.001 -0.887 <0.001 
 PUThigher -0.833 <0.001 -0.853 <0.001 
 CAUDlower -0.760 <0.001 -0.781 <0.001 
 CAUDhigher -0.721 <0.001 -0.731 <0.001 
Manual PUTlower -0.839 <0.001 -0.846 <0.001 
 PUThigher -0.810 <0.001 -0.829 <0.001 
 CAUDlower -0.791 <0.001 -0.808 <0.001 
 CAUDhigher -0.743 <0.001 -0.770 <0.001 
PUT=putamen; CAUD=caudate; lower means the more affected side with lower specific uptake ratio; 
higher means the less affected side with higher specific uptake ratio; ρ=Spearman's correlation 
coefficient; P=statistical P-value; Visual1=visual grades by Observer1; Visual2=visual grades by 
Observer2 
Table(s)
Table 4. Correlations between uptake parameters and the severity of Parkinsonian syndrome 
Analysis method Region 
H&Y Disease duration 
MDS-UPDRS 
I 
MDS-UPDRS 
II 
MDS-UPDRS 
III 
MDS-UPDRS 
IV 
MDS-UPDRS 
Total 
ρ P ρ P ρ P ρ P ρ P ρ P ρ P 
Automated PUTlower -0.433 0.012 -0.638 <0.001 -0.002 0.991 -0.349 0.047 -0.390 0.025 -0.359 0.040 -0.370 0.034 
 PUThigher -0.396 0.022 -0.648 <0.001 -0.028 0.876 -0.287 0.106 -0.303 0.087 -0.301 0.089 -0.325 0.065 
 CAUDlower -0.497 0.003 -0.601 <0.001 -0.080 0.659 -0.343 0.051 -0.288 0.104 -0.395 0.023 -0.356 0.042 
 CAUDhigher -0.445 0.010 -0.597 <0.001 -0.094 0.603 -0.340 0.053 -0.275 0.121 -0.380 0.029 -0.353 0.044 
Manual PUTlower -0.361 0.039 -0.655 <0.001 -0.093 0.608 -0.362 0.038 -0.362 0.039 -0.340 0.053 -0.395 0.023 
 PUThigher -0.300 0.090 -0.643 <0.001 -0.099 0.585 -0.368 0.035 -0.275 0.121 -0.260 0.144 -0.363 0.038 
 CAUDlower -0.446 0.009 -0.676 <0.001 -0.190 0.290 -0.404 0.020 -0.310 0.079 -0.379 0.029 -0.404 0.020 
 CAUDhigher -0.384 0.027 -0.635 <0.001 -0.189 0.291 -0.341 0.052 -0.230 0.198 -0.319 0.071 -0.336 0.056 
Visualmean – 0.411 0.018 0.693 <0.001 0.115 0.525 0.366 0.036 0.469 0.006 0.458 0.007 0.448 0.009 
H&Y=Hoehn-Yahr score; MDS-UPDRS= Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale; ρ=Spearman's 
correlation coefficient;  P=statistical P-value; PUT=putamen; CAUD=caudate; lower means the more affected side with lower specific uptake ratio; higher 
means the less affected side with higher specific uptake ratio; Visualmean=the visual grades averaged between the two observers 
Table(s)
